Posterior Segment Company Showcase - Notal vision at OIS@AAO 2016.
Presenter:
Quinton Oswald, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - QLTHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - QLT at OIS@AAO 2016.
Presenter:
David Saperstein, MD, Chief Medical Advisor
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Ohr pharmaceuticalHealthegy
Posterior Segment Company Showcase - Ohr pharmaceutical at OIS@AAO 2016.
Presenter:
Jason Slakter, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - PanOpticaHealthegy
Posterior Segment Company Showcase - PanOptica at OIS@AAO 2016.
Presenter:
Paul Chaney, Co-Founder, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnologies at OIS@AAO 2016.
Presenter:
Samuel B. Barone, MD SVP, Clinical Development
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Aura BiosciencesHealthegy
Posterior Segment Company Showcase - Aura Biosciences at OIS@AAO 2016.
Presenter:
Elisabet de los Pinos, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Graybug VisionHealthegy
Posterior Segment Company Showcase - Graybug Vision at OIS@AAO 2016.
Presenter:
Jeffrey Cleland, PhD, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Clearside BiomedicalHealthegy
Posterior Segment Company Showcase - Clearside Biomedical at OIS@AAO 2016.
Presenter:
Daniel White, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - QLTHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - QLT at OIS@AAO 2016.
Presenter:
David Saperstein, MD, Chief Medical Advisor
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Ohr pharmaceuticalHealthegy
Posterior Segment Company Showcase - Ohr pharmaceutical at OIS@AAO 2016.
Presenter:
Jason Slakter, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - PanOpticaHealthegy
Posterior Segment Company Showcase - PanOptica at OIS@AAO 2016.
Presenter:
Paul Chaney, Co-Founder, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnologies at OIS@AAO 2016.
Presenter:
Samuel B. Barone, MD SVP, Clinical Development
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Aura BiosciencesHealthegy
Posterior Segment Company Showcase - Aura Biosciences at OIS@AAO 2016.
Presenter:
Elisabet de los Pinos, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Graybug VisionHealthegy
Posterior Segment Company Showcase - Graybug Vision at OIS@AAO 2016.
Presenter:
Jeffrey Cleland, PhD, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Clearside BiomedicalHealthegy
Posterior Segment Company Showcase - Clearside Biomedical at OIS@AAO 2016.
Presenter:
Daniel White, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Ophthalmic Innovation 2016 - "A View From The AAO"Healthegy
Ophthalmic Innovation 2016 - "A View From The AAO"
Presenter:
David Parke, II, MD, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - OptheaHealthegy
Posterior Segment Company Showcase - Opthea at OIS@AAO 2016.
Presenter:
Megan Baldwin, PhD, CEO & Managing Director
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Ophthalmic Innovation 2016 - "A View From The NEI"Healthegy
The National Eye Institute (NEI) funds vision research through its $707 million annual budget. Its Audacious Goal Initiative aims to regenerate neurons in the eye and visual system by focusing on photoreceptor loss, ganglion cell injury, and optic nerve regeneration. The NEI supports translational research through grants such as the NEI Translational Research Program and Small Business Grants. It also conducts intramural research including stem cell therapy and gene therapy clinical trials. The NEI commits $50 million annually to support large clinical trials through organizations like the Diabetic Retinopathy Clinical Research Network. It also trains students and clinicians in vision research through fellowship programs.
Public Device & Biopharma Ophthalmology Company Showcase - Inotek Pharmaceuti...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Inotek Pharmaceuticals at OIS@AAO 2016.
Presenter:
David Southwell, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - OmerosHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - Omeros at OIS@AAO 2016.
Presenter:
Leonard M. Blum, Chief Business & Commercial Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Aerie PharmaceuticalsHealthegy
This document summarizes information from Aerie Pharmaceuticals regarding their late-stage IOP-lowering products RhopressaTM and RoclatanTM. Key points include:
- RhopressaTM (netarsudil ophthalmic solution) NDA was filed in Q3 2016 based on positive results from two Phase 3 trials, Rocket 1 and Rocket 2.
- RoclatanTM (netarsudil/latanoprost ophthalmic solution) achieved statistical superiority over individual components in its Phase 3 trial Mercury 1 at all timepoints.
- Mercury 2 and Mercury 3 trials are ongoing to support the RoclatanTM NDA filing expected near year-end 2017
Posterior Segment Company Showcase - AGTCHealthegy
Posterior Segment Company Showcase - AGTC at OIS@AAO 2016.
Presenter:
Sue Washer, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - AvedroHealthegy
Anterior Segment Company Showcase - Avedro at OIS@AAO 2016.
Presenter:
Rajesh K. Rajpal, MD, Chief Medical Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Aerie Pharmaceuticals is developing Rhopressa and Roclatan as once-daily eye drops to lower intraocular pressure for glaucoma. Rhopressa demonstrated efficacy in Phase 3 trials and Aerie expects to file an NDA in Q3 2016. Roclatan achieved all endpoints in a Phase 2b trial and is now in Phase 3 trials. Preclinical research also shows Rhopressa may modify diseased tissue and increase blood flow in the eye. Aerie is exploring AR-13154 for wet AMD which showed lesion size reduction exceeding the leading product in studies. The company collaborates with other organizations on delivery technologies and product candidates for the front and back of the eye.
OPT-302 is a soluble form of VEGFR-3 that inhibits VEGF-C and VEGF-D, blocking their binding to VEGFR-2 and VEGFR-3. It is being developed in combination with anti-VEGF-A therapies for the treatment of wet AMD. A Phase 1/2A clinical trial is actively recruiting wet AMD patients to evaluate the safety, pharmacokinetics, and efficacy of multiple doses of intravitreal OPT-302 in combination with ranibizumab. Preliminary data is expected in early 2016, with the goal of demonstrating OPT-302 can improve outcomes when added to anti-VEGF-A therapy by more completely suppressing the VEGF pathway.
This presentation discusses forward-looking statements and risks associated with them. It notes that while management believes expectations in forward-looking statements are reasonable, actual results could differ materially due to known and unknown risks and uncertainties. The presentation also notes that views expressed as of the date may change in the future.
Presentation from OIS@ASCRS 2016
Amar Sawhney, PhD, President, CEO & Chairman
Video Presentation:
https://www.youtube.com/watch?v=nGQzo6czij0&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=31
This document discusses a clinical trial being conducted by Ocata Therapeutics to evaluate the safety and efficacy of retinal pigment epithelium (RPE) cell transplantation for dry age-related macular degeneration (AMD). Previous phase 1 trials showed anatomical engraftment and functional improvement in vision. The current phase 2 trial will evaluate three regimens of short-term immunosuppression to prevent rejection of the transplanted cells. Safety will be the primary outcome measured with the goal of establishing a protocol to maintain graft survival without long-term immunosuppression.
Spark Therapeutics is developing gene therapies for genetic disorders including SPK-RPE65 for retinal diseases. SPK-RPE65 achieved highly statistically significant results in a pivotal Phase 3 trial, demonstrating long-lasting benefits on vision tests over 3 years. If approved, it could be the first gene therapy approved in the US for a genetic disease. Spark is applying its validated AAV gene therapy platform to expand its pipeline to additional retinal diseases and indications.
The document summarizes the development of an anti-VEGF eye drop called PAN-90806 being developed by PanOptica for the treatment of wet age-related macular degeneration and other retinal diseases. It describes positive preliminary results from a Phase 1/2 clinical trial in wet AMD patients showing biological activity with no systemic side effects. It also outlines plans to further study PAN-90806 using an advanced formulation in additional clinical trials for wet AMD and proliferative diabetic retinopathy. Developing an effective anti-VEGF eye drop could provide significant benefits over frequent eye injections.
Anterior Segment Company Showcase - Sensimed AGHealthegy
Anterior Segment Company Showcase - Sensimed AG at OIS@AAO 2016.
Presenter:
David Bailey, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Allegro OphthalmicsHealthegy
The document summarizes results from a phase 2b clinical trial of Luminate, a novel anti-integrin product being developed by Allegro Ophthalmics for the treatment of retinal diseases. The trial met its primary endpoint, showing Luminate was non-inferior to Avastin for improving visual acuity in patients with diabetic macular edema, with half as many injections. Luminate also met secondary endpoints for anatomical improvements measured by OCT. The results demonstrate the potential for Luminate as a well-tolerated monotherapy option with 12 weeks of durability through a new mechanism of action.
1) The document discusses Ophthotech's development of new therapies for age-related macular degeneration (AMD), including their lead drug Fovista.
2) Fovista is currently in Phase 3 clinical trials in combination with anti-VEGF drugs to treat wet AMD, with initial data expected in 4Q 2016.
3) Previous Phase 2b results showed Fovista in combination with Lucentis was statistically superior to Lucentis alone and had a favorable safety profile.
Posterior Segment Company Showcase - Alimera SciencesHealthegy
Posterior Segment Company Showcase - Alimera Sciences at OIS@AAO 2016.
Presenter:
Dan Myers, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Apellis PharmaceuticalsHealthegy
Posterior Segment Company Showcase - Apellis Pharmaceuticals at OIS@AAO 2016.
Presenter:
Cedric Francois, MD, PhD, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Ophthalmic Innovation 2016 - "A View From The AAO"Healthegy
Ophthalmic Innovation 2016 - "A View From The AAO"
Presenter:
David Parke, II, MD, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - OptheaHealthegy
Posterior Segment Company Showcase - Opthea at OIS@AAO 2016.
Presenter:
Megan Baldwin, PhD, CEO & Managing Director
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Ophthalmic Innovation 2016 - "A View From The NEI"Healthegy
The National Eye Institute (NEI) funds vision research through its $707 million annual budget. Its Audacious Goal Initiative aims to regenerate neurons in the eye and visual system by focusing on photoreceptor loss, ganglion cell injury, and optic nerve regeneration. The NEI supports translational research through grants such as the NEI Translational Research Program and Small Business Grants. It also conducts intramural research including stem cell therapy and gene therapy clinical trials. The NEI commits $50 million annually to support large clinical trials through organizations like the Diabetic Retinopathy Clinical Research Network. It also trains students and clinicians in vision research through fellowship programs.
Public Device & Biopharma Ophthalmology Company Showcase - Inotek Pharmaceuti...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Inotek Pharmaceuticals at OIS@AAO 2016.
Presenter:
David Southwell, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - OmerosHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - Omeros at OIS@AAO 2016.
Presenter:
Leonard M. Blum, Chief Business & Commercial Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - Aerie PharmaceuticalsHealthegy
This document summarizes information from Aerie Pharmaceuticals regarding their late-stage IOP-lowering products RhopressaTM and RoclatanTM. Key points include:
- RhopressaTM (netarsudil ophthalmic solution) NDA was filed in Q3 2016 based on positive results from two Phase 3 trials, Rocket 1 and Rocket 2.
- RoclatanTM (netarsudil/latanoprost ophthalmic solution) achieved statistical superiority over individual components in its Phase 3 trial Mercury 1 at all timepoints.
- Mercury 2 and Mercury 3 trials are ongoing to support the RoclatanTM NDA filing expected near year-end 2017
Posterior Segment Company Showcase - AGTCHealthegy
Posterior Segment Company Showcase - AGTC at OIS@AAO 2016.
Presenter:
Sue Washer, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - AvedroHealthegy
Anterior Segment Company Showcase - Avedro at OIS@AAO 2016.
Presenter:
Rajesh K. Rajpal, MD, Chief Medical Officer
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Aerie Pharmaceuticals is developing Rhopressa and Roclatan as once-daily eye drops to lower intraocular pressure for glaucoma. Rhopressa demonstrated efficacy in Phase 3 trials and Aerie expects to file an NDA in Q3 2016. Roclatan achieved all endpoints in a Phase 2b trial and is now in Phase 3 trials. Preclinical research also shows Rhopressa may modify diseased tissue and increase blood flow in the eye. Aerie is exploring AR-13154 for wet AMD which showed lesion size reduction exceeding the leading product in studies. The company collaborates with other organizations on delivery technologies and product candidates for the front and back of the eye.
OPT-302 is a soluble form of VEGFR-3 that inhibits VEGF-C and VEGF-D, blocking their binding to VEGFR-2 and VEGFR-3. It is being developed in combination with anti-VEGF-A therapies for the treatment of wet AMD. A Phase 1/2A clinical trial is actively recruiting wet AMD patients to evaluate the safety, pharmacokinetics, and efficacy of multiple doses of intravitreal OPT-302 in combination with ranibizumab. Preliminary data is expected in early 2016, with the goal of demonstrating OPT-302 can improve outcomes when added to anti-VEGF-A therapy by more completely suppressing the VEGF pathway.
This presentation discusses forward-looking statements and risks associated with them. It notes that while management believes expectations in forward-looking statements are reasonable, actual results could differ materially due to known and unknown risks and uncertainties. The presentation also notes that views expressed as of the date may change in the future.
Presentation from OIS@ASCRS 2016
Amar Sawhney, PhD, President, CEO & Chairman
Video Presentation:
https://www.youtube.com/watch?v=nGQzo6czij0&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=31
This document discusses a clinical trial being conducted by Ocata Therapeutics to evaluate the safety and efficacy of retinal pigment epithelium (RPE) cell transplantation for dry age-related macular degeneration (AMD). Previous phase 1 trials showed anatomical engraftment and functional improvement in vision. The current phase 2 trial will evaluate three regimens of short-term immunosuppression to prevent rejection of the transplanted cells. Safety will be the primary outcome measured with the goal of establishing a protocol to maintain graft survival without long-term immunosuppression.
Spark Therapeutics is developing gene therapies for genetic disorders including SPK-RPE65 for retinal diseases. SPK-RPE65 achieved highly statistically significant results in a pivotal Phase 3 trial, demonstrating long-lasting benefits on vision tests over 3 years. If approved, it could be the first gene therapy approved in the US for a genetic disease. Spark is applying its validated AAV gene therapy platform to expand its pipeline to additional retinal diseases and indications.
The document summarizes the development of an anti-VEGF eye drop called PAN-90806 being developed by PanOptica for the treatment of wet age-related macular degeneration and other retinal diseases. It describes positive preliminary results from a Phase 1/2 clinical trial in wet AMD patients showing biological activity with no systemic side effects. It also outlines plans to further study PAN-90806 using an advanced formulation in additional clinical trials for wet AMD and proliferative diabetic retinopathy. Developing an effective anti-VEGF eye drop could provide significant benefits over frequent eye injections.
Anterior Segment Company Showcase - Sensimed AGHealthegy
Anterior Segment Company Showcase - Sensimed AG at OIS@AAO 2016.
Presenter:
David Bailey, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Allegro OphthalmicsHealthegy
The document summarizes results from a phase 2b clinical trial of Luminate, a novel anti-integrin product being developed by Allegro Ophthalmics for the treatment of retinal diseases. The trial met its primary endpoint, showing Luminate was non-inferior to Avastin for improving visual acuity in patients with diabetic macular edema, with half as many injections. Luminate also met secondary endpoints for anatomical improvements measured by OCT. The results demonstrate the potential for Luminate as a well-tolerated monotherapy option with 12 weeks of durability through a new mechanism of action.
1) The document discusses Ophthotech's development of new therapies for age-related macular degeneration (AMD), including their lead drug Fovista.
2) Fovista is currently in Phase 3 clinical trials in combination with anti-VEGF drugs to treat wet AMD, with initial data expected in 4Q 2016.
3) Previous Phase 2b results showed Fovista in combination with Lucentis was statistically superior to Lucentis alone and had a favorable safety profile.
Posterior Segment Company Showcase - Alimera SciencesHealthegy
Posterior Segment Company Showcase - Alimera Sciences at OIS@AAO 2016.
Presenter:
Dan Myers, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Apellis PharmaceuticalsHealthegy
Posterior Segment Company Showcase - Apellis Pharmaceuticals at OIS@AAO 2016.
Presenter:
Cedric Francois, MD, PhD, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
Mike Judy, CEO
Video of Presentation:
https://www.youtube.com/watch?v=G5ZfnPKlBSY&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=13
Anterior Segment Company Showcase - SightLifeHealthegy
Anterior Segment Company Showcase - SightLife at OIS@AAO 2016.
Presenter:
Monty Montoya, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
Presentation from OIS@ASCRS 2016
James Brandt, MD, Principal Investigator
Video Presentation:
https://www.youtube.com/watch?v=jvIozhPMSQ8&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=30
Posterior Segment Company Showcase - Ocular TherapeutixHealthegy
Posterior Segment Company Showcase - Ocular Therapeutix at OIS@AAO 2016.
Presenter:
Amar Sawhney, PhD, President, CEO & Chairman
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - AerpioHealthegy
Posterior Segment Company Showcase - Aerpio at OIS@AAO 2016.
Presenter:
Joseph Gardner, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
This document discusses microinvasive glaucoma surgery (MIGS) and the growing market potential for MIGS devices. It provides an overview of current glaucoma treatment options and their limitations. The author estimates that there are currently around 250,000 glaucoma surgeries performed annually in the US, but that the potential market for MIGS devices could be much larger given the number of glaucoma patients on multiple medications who could be candidates for MIGS. Financial data is presented for one company demonstrating the growth in the MIGS market.
This presentation summarizes ACT's regenerative medicine business, including its retinal pigment epithelium (RPE) clinical program and mesenchymal stem cell and blood components programs. Key points include:
1) ACT is developing RPE cells derived from human embryonic stem cells to treat dry age-related macular degeneration and Stargardt's macular dystrophy. Its Phase I clinical trials for both conditions have shown no safety issues to date.
2) Preliminary results from the RPE clinical trials show signs of engraftment and survival of transplanted cells, as well as functional visual improvements in some patients.
3) ACT is also developing mesenchymal stem cells and blood components
This presentation summarizes ACT's regenerative medicine business, including its retinal pigment epithelium (RPE) clinical program and mesenchymal stem cell and blood components programs. Key points include:
1) ACT is developing RPE cells derived from human embryonic stem cells to treat dry age-related macular degeneration and Stargardt's macular dystrophy. Its Phase I clinical trials for both conditions show no safety issues and preliminary signs of efficacy.
2) ACT is also developing mesenchymal stem cells derived from pluripotent stem cells for treating autoimmune and inflammatory diseases, as well as blood components like platelets produced at scale from hemangioblast precursors.
3
Νικόλαος Κουρεντζής, Country Head Radiology-Ελλάδα, Κύπρος, Ισραήλ, Ρουμανία, Βουλγαρία, Μάλτα και Μολδαβία, Bayer
«Οι νέες προκλήσεις στην ιατρική απεικόνιση»
This document discusses the implantable miniature telescope (IMT) for treating end-stage age-related macular degeneration. It provides the following information:
1) The IMT received FDA approval in 2009 and Medicare coverage in 2011-2012 for patients with untreatable end-stage AMD who meet clinical criteria.
2) Clinical trials showed the IMT significantly improved vision for most patients, with 67% gaining 3 or more lines of vision and quality of life improvements.
3) The CentraSight treatment program assesses patients' candidacy and provides pre-and post-operative management including low vision rehabilitation to help patients utilize their restored vision.
VSN.st has developed a new tool to facilitate safe, fast, targeted, simple and repeatable injections of intraocular and suprachoroidal pharmaceuticals.
The document is an investor presentation by ACT that summarizes their regenerative medicine programs focused on ocular diseases. Key points include:
- ACT has programs focused on developing retinal pigment epithelial (RPE) cells, hemangioblast cells, retinal neural progenitor cells, corneal endothelial cells, and mesenchymal stromal cells for various ocular diseases.
- Clinical trials are underway testing RPE cells derived from human embryonic stem cells for Stargardt's macular dystrophy and dry age-related macular degeneration. Early results show safety and signs of efficacy.
- The company has proprietary technologies for deriving human embryonic stem cells without destroying embryos, as well as for generating induced pl
This document provides an overview of Advanced Cell Technology's (ACT) regenerative medicine programs and pipeline. ACT is developing cell therapy products for ophthalmology using retinal pigment epithelial (RPE) cells and retinal neural progenitor cells derived from pluripotent stem cells. ACT has completed Phase I clinical trials of RPE cells for dry age-related macular degeneration and Stargardt's macular dystrophy with no adverse events reported and signs of visual improvement. The company is also developing mesenchymal stem cells for treating autoimmune and inflammatory diseases. ACT has a robust intellectual property portfolio and is led by an experienced management team and board of directors.
ACT is conducting three clinical trials for dry age-related macular degeneration (AMD) and Stargardt's disease (SMD) using retinal pigment epithelium (RPE) cells derived from human embryonic stem cells. The trials have shown no adverse events and persistence of the transplanted cells, with functional vision improvements in most patients. ACT has additional clinical programs planned or underway for myopic macular degeneration and has a pipeline of other ophthalmology and regenerative medicine programs. It has strong intellectual property around RPE cell production and therapy. Upcoming milestones include further patient follow-up data and the potential start of Phase II trials. ACT is led by an experienced management team and board of directors.
Visionisti Oy is a privately held company, which is specialized in developing and commercializing a new suprachoroidal injection tool for ophthalmic drug delivery.
IRJET- Detection of Diabetic Retinopathy using Convolutional Neural NetworkIRJET Journal
This document describes research using a convolutional neural network to detect diabetic retinopathy from fundus images. The researchers trained a CNN model on a dataset of over 35,000 fundus images to classify images into five stages of diabetic retinopathy severity. The CNN model extracts features from input fundus images and uses activation functions and optimization algorithms to output a classification. The classification along with patient details will generate a standardized report on diabetic retinopathy detection and diagnosis.
What is Light Induced Visual-response (LIV)?Diopsys, Inc.
Light Induced Visual-response (LIV) measures the electrical responses of cells within the eye upon stimulation by a light source. Various stimuli can be used to target different cells within the visual pathway to gain objective information regarding their function, thus allowing clinicians to detect even subtle changes in cell health and viability. With objective, functional data, Light Induced Visual-response (LIV) allows for tailored treatment and more precise disease management.
Original publication: http://info.diopsys.com/blog/light-induced-visual-response-liv
IJRET : International Journal of Research in Engineering and Technology is an international peer reviewed, online journal published by eSAT Publishing House for the enhancement of research in various disciplines of Engineering and Technology. The aim and scope of the journal is to provide an academic medium and an important reference for the advancement and dissemination of research results that support high-level learning, teaching and research in the fields of Engineering and Technology. We bring together Scientists, Academician, Field Engineers, Scholars and Students of related fields of Engineering and Technology
Automatic identification and classification of microaneurysms for detection o...eSAT Journals
Abstract Headlights of vehicles pose a great danger during night driving. The drivers of most vehicles use high, bright beam while driving at night. This causes a discomfort to the person travelling from the opposite direction. He experiences a sudden glare for a short period of time. This is caused due to the high intense headlight beam from the other vehicle coming towards him from the opposite direction. We are expected to dim the headlight to avoid this glare. This glare causes a temporary blindness to a person resulting in road accidents during the night. To avoid such incidents, we have fabricated a prototype of automatic headlight dimmer. This automatically switches the high beam into low beam thus reducing the glare effect by sensing the approaching vehicle. It also eliminates the requirement of manual switching by the driver which is not done at all times. The construction, working and the advantages of this prototype model is discussed in detail in this paper. Keywords: Headlight, automatic, dimmer, control, high beam, low beam, Kelvin (K).
This document discusses a company called Spinea Medical that has developed an automated solution for lower back pain (LBP) diagnostics and analytics. It notes that LBP is a major global health issue, but current diagnostic methods are subjective, qualitative and provide limited information. Spinea Medical's solution takes a comparative and objective approach using medical imaging and big data to provide comprehensive and accurate analysis of the spine. It aims to measure and compare spinal features against general population data to give patients and clinicians a clean overview of spinal status and integrated abnormal findings. The company sees opportunities in the medical imaging market and plans clinical studies and partnerships to commercialize and achieve reimbursement for its technology.
Ron Najafi, Chairman and CEO of NovaBay Pharmaceuticals, provided an update to shareholders at their annual meeting. NovaBay is developing new anti-infective products to address the growing crisis of antibiotic resistance. Their lead product candidates include auriclosene, which has shown effectiveness against bacteria, viruses, and fungi in clinical trials for conditions like conjunctivitis and impetigo, without inducing resistance. NovaBay also markets NeutroPhase, a pure hypochlorous acid solution for wound care. They anticipate results from multiple global phase 2 clinical trials in 2013 and have established partnerships to commercialize their products in key markets.
This presentation summarizes ACT's regenerative medicine business. ACT is a biotechnology company developing cellular therapies for diseases affecting hundreds of millions. Their leading program is an RPE cell therapy for dry AMD currently in clinical trials. The therapy shows early promise with no safety issues reported. If successful, it could generate billions in revenue given the large patient population. ACT has a strong balance sheet and team to advance its pipeline of stem cell therapies targeting ocular diseases and conditions.
Diabetic retinopathy management an advanced approach gonzalezDiopsys, Inc.
Electroretinography (ERG) provides objective information about retinal function that can help doctors better manage diabetic retinopathy. Specifically, flicker ERG testing measures cone cell response and can identify early retinal changes, stage disease severity, and evaluate treatment effectiveness. By detecting functional changes not seen with visual acuity tests alone, ERG allows for improved decision-making regarding treatment options and goals of care for the millions of Americans with diabetic retinopathy.
Cognitive Computing: Company presentation by Avner Halperin, Co-Founder & CEO of EarlySense at the NOAH Conference 2019 in Tel Aviv, Hangar 11, 10-11 April 2019.
How AI Enhances & Accelerates Diabetic Retinopathy DetectionCognizant
To enable earlier and quicker diagnosis of diabetic retinopathy (DR), Cognizant has built a system based on AI and deep learning - a convolutional neural network - that analyzes many thousands of fundus images and delivers accurate assessments of eye-disease damage.
Similar to Posterior Segment Company Showcase - Notal vision (20)
This document provides an overview of a company called Aerie Pharmaceuticals and their glaucoma products. It summarizes clinical trial results for Rhopressa and Roclatan, which are novel glaucoma drugs. Rhopressa achieved non-inferiority compared to timolol in lowering eye pressure over 6 months in multiple trials. A pilot study found Rhopressa to be effective at lowering pressure during both day and night. Roclatan was statistically superior to its individual components latanoprost and Rhopressa in lowering pressure at all timepoints in a phase 3 trial. Both drugs were generally well tolerated with conjunctival hyperemia as the most common side effect.
This document provides an overview of a company called Aerie Pharmaceuticals and their glaucoma products. It summarizes results from clinical trials of their two leading investigational drug candidates, Rhopressa and Roclatan. Rhopressa achieved non-inferiority compared to timolol in lowering eye pressure over 6 months in phase 3 trials. A pilot study also found Rhopressa to be effective at lowering pressure during nighttime hours. Roclatan was found to be statistically superior to its individual components, latanoprost and Rhopressa, in lowering pressure at all timepoints in a phase 3 trial. Both drugs demonstrated favorable safety profiles in clinical testing.
This document discusses small aperture optics for improving vision, including the KAMRA corneal inlay and IC-8 intraocular lens. It summarizes clinical studies that show the KAMRA inlay and IC-8 IOL provide an extended depth of focus, improving intermediate and near vision while maintaining good distance vision. The document also notes that these technologies are capturing more market share and have the potential to address a significant segment of patients with aberrated corneas.
This document provides an overview of Avedro, the world leader in corneal remodeling. Key points include:
- Avedro has developed the first and only FDA-approved corneal cross-linking platform for treating keratoconus and corneal ectasia. They have installed 1500 systems and performed 250,000 treatments.
- Their 2017 plans are to expand into keratoconus and refractive markets, drive toward reimbursement, and conduct 14 clinical studies on epi-on procedures and refractive applications.
- They have a proven cross-linking mechanism of action that strengthens the cornea to stabilize keratoconus and ectasia. Their PiXL technique allows for non-invasive zonal strengthening to induce corneal
The document discusses Cassini, a corneal imaging system that provides comprehensive analysis of the anterior and posterior cornea to reduce refractive surprises. It has 6 key features: 1) total corneal analysis, 2) ocular surface diagnostics, 3) iris registration, 4) integrated surgical workflow, 5) data mining, and 6) proactive solutions. Cassini provides valuable pre-op information and seamlessly integrates with other technologies. It uses multi-colored LEDs and 2nd Purkinje imaging to map total corneal astigmatism. Cassini has been used in over 300,000 cataract patients to date. It can drive premium procedures and adoption of premium IOLs while also streamlining surgical workflows.
The HARMONI Modular IOL System provides a stable foundation through a reliable base and optimized rotational stability. Its modular design allows for versatile control through safe and easy optic exchangeability and upgradeability to provide refractive care for a patient's lifetime. Clinical trials show the HARMONI IOL has best-in-class stability and visual performance that rivals traditional IOLs, while offering the ability to fine tune outcomes through optic exchange. The system aims to provide complete confidence in surgical outcomes without added costs or changes to routines.
EyeGate Pharmaceuticals is developing two drug delivery platforms - a crosslinked hyaluronic acid eye drop called Ocular Bandage Gel to promote wound healing after corneal surgery or injuries, and an iontophoresis delivery system to administer the corticosteroid dexamethasone phosphate (EGP-437) after cataract surgery or for anterior uveitis. Positive pilot clinical trial data was announced for Ocular Bandage Gel in accelerating wound healing after photorefractive keratectomy. Later stage clinical trials are underway or planned for EGP-437 to reduce inflammation for cataract surgery and uveitis, with FDA filings targeted for 2018. EyeGate licensed worldwide commercial rights for EGP-
Ophthalmology Innovation Showcase 1 - InnFocus (A Santen Company)Healthegy
The InnFocus MicroShunt is designed to be the first FDA-approved standalone procedure to treat mild, moderate, and severe open-angle glaucoma by lowering intraocular pressure under 15 mmHg without eye drops in most patients. It uses a unique SIBS material that has been proven biocompatible and shown not to degrade or provoke scarring over 15 years of use in over 1 million patients. Clinical trials have demonstrated the MicroShunt's ability to successfully lower IOP long-term while maintaining an acceptable safety profile. The MicroShunt offers surgeons a potential replacement for trabeculectomy and tubes with advantages in both safety and operating time.
The document discusses the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device that provides a tri-modal mechanism of action to lower intraocular pressure. Over 3,200 patients have been treated globally using the Hydrus Microstent. Clinical studies and a large global registry have shown the Hydrus Microstent to provide superior outcomes compared to other MIGS devices, with a 20% reduction in diurnal intraocular pressure and increased treatment response rates. The Hydrus Microstent expands treatment opportunities for both standalone glaucoma procedures and combined cataract/glaucoma surgeries.
The LacriPen is a handheld portable device that can measure osmolality and biomarkers from tears in 1 second using surface plasmon resonance. It has achieved a goal of ±2 mOsms/L for osmolality measurements and can detect MMP-9 concentrations from 1-200 ng/ml with precision of ±5 ng/ml. Clinical testing of the LacriPen's ability to measure osmolality and detect smart diagnostics has been approved and initial testing has been completed. The portable design allows for point-of-care diagnostics without the need for anesthesia or eyelid scraping.
Ophthalmology Innovation Showcase 1 - Mati TherapeuticsHealthegy
This document discusses a punctal plug drug delivery system called Evolute. It can deliver drugs to treat various ocular diseases like glaucoma, allergies, inflammation, and dry eye. Clinical trials showed excellent plug retention rates over 12 weeks. The system offers benefits like a flexible drug delivery profile, non-invasive application, steady drug elution unlike eye drops, and comfort. It is developing formulations of nepafenac, difluprednate, travoprost, olopatadine, and cyclosporine to treat conditions like post-cataract pain/inflammation and glaucoma. The company has a strong intellectual property position and plans upcoming clinical trials.
ZeptoTM is a device that uses the Purkinje image to anchor cataract surgery on the visual axis. It completed a US clinical trial in 80 days and was submitted to the FDA for 510(k) clearance in March 2017. The device has launched in India, Germany, and is planned for the US summer 2017. Development is also underway for an automated ZeptoTM for posterior capsulotomy. ZeptoTM aims to increase practice efficiency, allow for difficult cases to be performed easily and safely, and has the potential to redefine cataract surgery.
Ocular Therapeutix is developing sustained-release drug therapies for ophthalmic conditions to improve patient outcomes and compliance. Their lead product, DEXTENZA, is an intracanalicular insert delivering dexamethasone for up to 30 days after cataract surgery to reduce pain and inflammation. Phase 3 trials showed DEXTENZA was well-tolerated and effective in meeting primary efficacy endpoints. If approved, DEXTENZA could become the new standard of care by replacing complex topical drop regimens. The company is also developing sustained-release therapies for glaucoma and posterior segment diseases in collaboration with Regeneron.
The document expresses gratitude but does not provide any further details. It is a very short document consisting of only two words with no other context provided.
The document discusses an artificial intraocular lens (AIOL) called the FluidVision that mimics the eye's natural accommodative process. It is the first true shape changing, fluid-driven IOL. Early results from a 23 patient pilot study show promising results with a straightforward surgical technique. Bench testing shows the FluidVision provides excellent image quality over a range of powers as it continuously varies between far and near focal points by inflating and deflating the lens using fluid movements. PowerVision is developing additional innovations like a toric version and post-implant adjustment capabilities.
The document discusses Presbia Flexivue Microlens, an investigational intracorneal inlay to treat presbyopia. It notes that there are 1.8 billion presbyopes worldwide and ophthalmologists are motivated to treat this large market. The technology involves implanting a small hydrophilic acrylic lens in the cornea using existing femtosecond lasers. The author's clinical experience found the procedure had a short learning curve, excellent uncorrected near vision, and distance vision was unaffected. The inlay shows potential for treating presbyopia, improving vision after cataracts or LASIK.
Presbyopia Therapies is developing LiquidVision Eye Drops to treat presbyopia, a large global market affecting most people over age 50. The drops aim to improve near vision without distance vision blur for 5+ hours after a single daily dose. Currently, the main treatment options are reading glasses or contact lenses. A phase 2a trial in 2016 showed the drops improved uncorrected near vision versus placebo. A phase 2b trial beginning in Q2 2017 aims to demonstrate a 30 minute onset and 5+ hour duration with a 3-line improvement in near vision. The company hopes to create a new global market category for the daily treatment of presbyopia.
This document summarizes information about the VisAbility Micro-Insert System, an investigational device for treating presbyopia. It provides details on the clinical trial results showing the device improved near vision without compromising distance vision. Over multiple time periods, a high percentage of patients achieved good near vision both with and without glasses. The device also showed stability in refractive error and high patient satisfaction rates. The summary concludes with benefits of the VisAbility procedure compared to other presbyopia surgeries, such as preserving full range of focus and stereopsis while having a superior safety profile.
The document discusses market research data on the presbyopic market in the US and patient outcomes and satisfaction rates for Raindrop vision correction surgery. It finds that there are over 28 million potential patients in the US, with 71% seeking an ophthalmologist for the procedure. Real-world data shows 99% of patients achieving less than 20/20 distance vision and 78% less than J3 near vision, with a low 2.5% explant rate. Surgeon, patient, and reorder satisfaction rates are over 90% based on recent surveys.
SightGlass Vision has developed lenses that can safely and effectively reduce myopia progression in children. Myopia is a growing global problem, with hundreds of millions expected to suffer vision impairment due to complications if left untreated. Current solutions are only marginally effective and carry safety risks. SightGlass lenses work by providing peripheral blur and reducing peripheral hyperopia based on clinical trials, demonstrating over a 90% reduction in axial eye growth. The company is seeking funding to conduct a pivotal study and launch the lenses globally to address this major public health issue.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
2. [ 2 ]
A NEW PARADIGM FOR THE
Detection
of Ocular Diseases
FI RST APPLI C ATI ON
Age-Related Macular Degeneration (AMD)
The #1 Cause of Vision Loss in People 60+*
… in diseases where early detection
can dramatically affect outome
* In developed countries
P H Y S I C I A N - D R I V E N
Diagnosis and Treatment
PAT I E N T- A C T I VAT E D
Detection
T E C H N O L O G Y - E N A B L E D
3. [ 3 ]
AMD Innovation Focused on
Physician-Driven Diagnosis and Treatment
1MarketsandMarkets Report 2 GlobalData estimate of 2023 AMD Global Treatment Market
ACCURATE
DIAGNOSIS
EFFECTIVE
TREATMENT
Optical Coherence
Tomography
(OCT)
Anti-VEGFs
and
Future Novel
Therapies
Driving
Significant Markets HOWEVER:
$1B1
~$10B2
Detection Is
Not Timely
Treatment
Demonstrates Efficacy
but Functional Vision
May Never Be
Restored
5. [ 5 ]
Visual
Acuity
Severe
Vision
Loss
Dry AMD Wet AMD
Downward
Cascade in Vision
Loss May Go
Unnoticed by
Patients
The Challenge: Timely Detection of Wet AMD
Slow
Progression
Rapid
Progression
Therapeutics (e.g. Anti
VEGFs)
Treat Wet Form Only
Within Weeks:
Narrow Window to Detect
Transition from Wet Dry
Finding Patients at the Turning
Point of Disease …
… So Early Treatment Can
Preserve Functional Vision
… 36 Million Globally with AMD
THE DETECTION ‘LOTTERY’
THE CHALLENGE:
6. [ 6 ]
Today: Vast Majority of Wet AMD Patients
Are Diagnosed Too Late
Driving Threshold
i.e., ‘Functional Vision’
Normal
Legal
Blindness
20/200
20/40
20/20
TODAY’S REALITY
Lost with Late Dx Gained with Tx
-18 Letters
+8 Letters
~70%
*
Below
20/40
20/40+
No Longer Have
Functional Vision at
Diagnosis
BASELINE
May Not Regain Functional
Vision with Treatment
… and
* Analysis of Multiple AMD Studies
7. [ 7 ]
Current Disease Detection Options
Are Too Infrequent or Insensitive
Low
High
CLINICAL
ROBUSTNESS
HighLow CONVENIENCE / FREQUENCY
Household
Items
Amsler Grid
Smartphone Apps
At Home
Patient-Activated
Detection
The Holy Grail
In-Office OCT
Physician-Driven
Diagnosis
8. [ 8 ]
CLINICAL
ROBUSTNESS
• 94% Maintained
Functional Vision
(20/40+) in NIH Study
• Objective measure
• Sensitive
Our Pioneering Innovation: Patient-Activated,
Clinically Robust Early Disease Detection
CONVENIENCE
• 3 minute test per eye
• Unique design tailored to
older patient population
– Device and Technology
ecosystem
• “Plug and play”
• Results sent directly
to physician
PROVEN
Preferential Hyperacuity Perimetry
(PHP)
Detects Onset of Neovascular Leakage within
DAYS vs. Week / Months Before Patients Would
Notice Change
3,000+
Patients
2 Million
Tests
4-5x/Week
(for avg. 3.3 yrs)
FDA
Cleared
CE
Marked
Medicare
Coverage
9. [ 9 ]
Alert – in event of statistically
significant change
5Reminder
calls
3
CLOUD HOSTING
Notal Vision
Data Monitoring
Center
A Complete, Personalized Monitoring System
Early Detection in Action
OUR ENGINE ROOM IN THE CLOUD
• High touch
• Technology-enabled
• Scalable
• Compliant and secure
• Fully integrated billing/reimbursement
1 Patient takes test daily
PHYSICIAN
Physician office calls patient
for office visit and treatment
6
Data automatically
sent via embedded
cellular modem
2 Ongoing monitoring
• Monthly reports pushed
• Online access
4
PATIENT
10. [ 10 ]
COMPLEMENTARY
Finally Completing the Missing Link
for AMD Treatment and Diagnosis
PHYSICIAN-DRIVEN
Formal Diagnosis
and Treatment with
Effective Current and
Future Therapies
2006
PATIENT-ACTIVATED
Convenient, Objective,
Accurate Early Detection
2016
THE NEW
REALITY
Taking AMD Treatment to
the Next Level
...
Shift from
Regaining Vision ...
...to Not Losing It in
the First Place
Enabling
Timely Treatment